Frequency ExchangeFRECF -32.52%8 Debt-to-EBITDA is -0.30 as of Mar. 2026. GuruFocus rates FRECF with a GF Score™ of 8/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 467 Medical Devices & Instruments companies, Frequency Exchange ranks worse than 214132.55% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Frequency Exchange's Debt-to-EBITDA or its related term are showing as below:
FRECF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.59 Med: -0.37 Max: -0.15
Current: -0.25
During the past 6 years, the highest Debt-to-EBITDA Ratio of Frequency Exchange was -0.15. The lowest was -0.59. And the median was -0.37.
FRECF's Debt-to-EBITDA is ranked worse than 100% of 467
companies
in the Medical Devices & Instruments industry
Industry Median: 1.54
vs FRECF: -0.25
Frequency Exchange (OTCPK:FRECF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Frequency Exchange Debt-to-EBITDA Related Terms
Frequency Exchange Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Frequency Exchange's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Frequency Exchange's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frequency Exchange Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Frequency Exchange's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Frequency Exchange's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Frequency Exchange (FRECF) has a Debt-to-EBITDA of -0.30 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Frequency Exchange. According to the industry distribution chart, Frequency Exchange ranks #999999 out of 467 companies in the Medical Devices & Instruments industry.
Is Frequency Exchange's Debt-to-EBITDA too high?
Frequency Exchange's current Debt-to-EBITDA is -0.30. Based on the distribution chart, Frequency Exchange ranks #999999 out of 467 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Frequency Exchange has a GF Score™ of 8/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Frequency Exchange's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Frequency Exchange ranks #999999 out of 467 companies for Debt-to-EBITDA. This places Frequency Exchange in the lower half of its industry. The industry median Debt-to-EBITDA is 1.54. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.54, based on 467 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Frequency Exchange. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Frequency Exchange's current Debt-to-EBITDA is -0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frequency Exchange stock overvalued right now?
Based on GuruFocus' analysis, Frequency Exchange (FRECF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.16 — trading 100% above its estimated fair value. The current Debt-to-EBITDA is -0.30. Frequency Exchange's overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Frequency Exchange (FRECF), the current Debt-to-EBITDA is -0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frequency Exchange (FRECF) Overvalued in 2026?
Based on GuruFocus' analysis, Frequency Exchange stock appears to be overvalued.
The current stock price of $0.16 is trading 100% above its estimated GF Value™ of $0.08.
GuruFocus considers Frequency Exchange to be Significantly Overvalued.
Key valuation signals for FRECF:
Debt-to-EBITDA: -0.30
GF Value™: $0.08 vs. price of $0.16 (100% above fair value)
No single metric tells the full story. See the FRECF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Frequency Exchange Corp is focused on the development and world-wide commercialization of a wearable Frequency Delivery System providing specialized programs designed for health and wellness as well as performance enhancement. The company has one operating and reportable segment which the sale of wearable devices. Geographically, it operates in Canada; United States; and International.
8GF Score
Get the complete analysis for FRECF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRECF has been successfully added to your 
